This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeClinical InformationClinical InformationACIP RecommendationsWhat is TicoVac®?What is TBE?Symptoms & Risk FactorsDemonstrated EffectivenessDosing & Administration ScheduleResourcesResourcesMaterialsVideosOrder TicoVac®
Prescribing Information Indication Patient Site
Help Your Patients Understand the RisksTBE is a rare but serious viral infectious disease involving the central nervous system with potentially lifelong consequences.1,2

Among adults infected with the European subtype, two-thirds will only experience phase one.3 After about 8 days of no symptoms, 20-30% of patients will experience a second phase.3 Of those that experience both phases, about 30-60% will develop long-term sequelae.3​​​​​​​

Symptoms of TBE and Its Key Facts

TBE symptoms can be initially mistaken for a mild flu-like illness.4

Symptoms of TBE typically appear in two distinct phases, with specific symptoms for each phase.5​​​​​​​

Phase 1
In the initial phase, patients may experience muscle pain, headache, fatigue, and a temperature of 99.5-102.2oF for 2 to 7 days.5 Patients may then have a period of 2 to 10 days with no symptoms.5Phase 2
The second phase presents more serious symptoms consistent with meningitis, such as fever, headache, and stiff neck.3 In the European subtype, ~50% of patients present with meningitis, particularly children.5,6 Symptoms in this phase may include high fever, headache, nausea, vomiting, and vertigo.5​​​​​​​​​​​​​​Risk Factors for TBE

TBE can be transmitted to humans within minutes of a single bite from an infected tick.7,8

Environmental changes and human behavior are helping ticks cross geographic boundaries into new areas.9

*Data is from non-US travelers.

  • Patients are at an increased risk when traveling to countries within Europe and Asia where tick-borne encephalitis is endemic.11 Patients are also at risk of TBEV exposure when consuming unpasteurized dairy products that have been contaminated with the virus.1
  • Certain activities can put your patients at risk of being bitten by a tick including hiking, camping, visiting a park, gardening, among other outdoor-related activities.7,11
  • If your patients are planning on traveling to European or Asian countries, consider having a conversation with them regarding starting the TicoVac® vaccination series.12 The dosage series is made up of 3 separate doses, which must be completed at least seven days before patients plan on embarking to endemic countries.12
  • There are other methods for helping to avoid tick bites, especially in those countries where the TBE virus is endemic, including wearing clothing that covers the entire body when traveling in areas that are wooded or grassy.4 Additionally, the need to check for ticks after being in these areas is a must.4
Lifelong Consequences
  • Disorders that affect coordination, balance, and speech11
  • Cognitive changes – leading to memory loss, inability to concentrate, and mood change13
  • Muscle weakness or permanent paralysis13
  • Temporary or long-term loss of consciousness13
  • In very rare cases, death may occur3
Vaccination is an effective prevention method for TBE1,12TBE is a rare viral infection for which there is no effective cure.7,12 There is currently no specific treatment for TBE, only management of symptoms.7,12
 
Contact your Pfizer Customer Service Representative at
​​​​​​​1-800-666-7248.
 
References:Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-1871. doi:10.1016/S0140-6736(08)60800-4Barrett PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine. 2003;21 (suppl 1):S41-S49. doi:10.1016/s0264-410x(02)00814-9Centers for Disease Control and Prevention. Tick-born encephalitis fact sheet. Accessed February 9, 2022. https://www.cdc.gov/vhf/tbe/pdf/factsheet.pdf.Travel Health Pro. Disease in brief. Tick-borne encephalitis. Accessed February 9, 2022. https://travelhealthpro.org.uk/disease/173/tick-borne-encephalitis.Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am. 2008;22(3):561-575. doi:10.1016/j.idc.2008.03.013Bogovic P, Strle F. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin Cases. 2015;3(5):430-441. doi:10.12998/wjcc.v3.i5.430Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th ed. Global Health Press; 2021.European Centre for Disease Prevention and Control. Factsheet about tick-borne encephalitis (TBE). Accessed February 9, 2022. https://www.ecdc.europa.eu/en/tick-borne-encephalitis/facts/factsheet.Michelitsch A, Wernike K, Klaus C, Dobler G, Beer M. Exploring the reservoir hosts of tick-borne encephalitis virus. Viruses. 2019;11(7):1-17. doi:10.3390/v11070669Rendi-Wagner P. Risk and prevention of tick-borne encephalitis in travelers. J Travel Med. 2004;11(5):307-312. doi:10.2310/7060.2004.19107Fischer M, Gould CV, Rollin PE. Tickborne Encephalitis. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017. Chap 4. Accessed February 9, 2022. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/tickborne-encephalitis.TicoVac® (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.Haglund M, Günther G. Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up. Vaccine. 2003;21(suppl 1):S11-S18. doi:10.1016/s0264-410x(02)00811-3
DEMONSTRATED EFFECTIVENESS

TicoVac® is >96% effective in preventing hospitalized TBE.12

 Review effectiveness Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TCV-USA-0190
INDICATION AND USAGE TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
IMPORTANT SAFETY INFORMATION
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events.You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Please see full prescribing information for TicoVac® here.
Indication TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.Important Safety Information
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
 Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. Please see full prescribing information for TicoVac® here. Indication
TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367